UPDATE ENV105 moves to the randomized part of phase 2 trial

[Maxone73]

I have already written about this, it is, in a nutshell, a drug that prevents or reverses resistance to existing ARSIs.

The safety lead-in phase of a Phase 2 trial for ENV105, an innovative therapy for metastatic, castration-resistant prostate cancer (mCRPC), has been successfully completed.

The trial, conducted at leading cancer centers, combines ENV105 with apalutamide to address treatment resistance.

Preliminary safety and efficacy data are expected in the first half of 2025, with patient enrollment for the randomization arm ongoing. Supported by the National Cancer Institute and focused on biomarker validation, this research aims to identify patients who may benefit most from the therapy.

prostatewarriors.com/2025/0...